ATCC’s Ruth Cheng Expands Role to Vice President of Corporate Development
ATCC, the world’s premier biological materials management and standards organization, today announced the expanded role of Ruth Cheng, Ph.D., Chief Strategy and Innovation Officer to include duties as Vice President of Corporate Development.
Since January 2020, Cheng has led the development of a short and long-term corporate strategic plan and launched the Innovation Hub that has invested in over a dozen employee-led discoveries. Cheng began her career at Boston Scientific, where she established and managed a corporate innovation team. She then joined Smith & Nephew as their Director of Innovation and Strategy. And before joining ATCC, Cheng served as Vice President of Global Strategy for AgNovos Healthcare.
Cheng received her Master’s and Doctorate in Biomedical Engineering from the University of Michigan and her Bachelor of Arts in Biological Sciences from Cornell University. She holds executive certificates in Strategy and Innovation from MIT Sloan and Private Equity and Venture Capital from Harvard Business School. In addition to authoring numerous scientific publications and more than a dozen patents, she also is an invited lecturer at congresses and universities on medical technology innovation.
“Over the past year, Ruth has been instrumental in driving the company’s strategic planning processes and strengthening relationships with our key stakeholders,” said Raymond H. Cypess, DVM, Ph.D., Chairman and CEO of ATCC. “She has been a catalyst for change at ATCC, and we look forward to her taking on a larger role in identifying new opportunities with an eye towards maximizing the efficiency of ATCC’s business operations and expanding its global products and service offerings.”
ATCC is a premier global biological materials and information resource and standards organization and the leading developer and supplier of authenticated cells lines and microorganisms. With a history of scientific advancements spanning nearly a century, ATCC offers an unmatched combination of being the world’s largest and most diverse collection of biological research solutions and a mission-driven, trusted partner that supports and encourages scientific collaboration. ATCC products, services, and people provide the scientific community with credible biological products, advanced model systems, and custom solutions that support complex research in a variety of innovative applications resulting in incredible achievements in basic science, drug discovery, translational medicine, and public health. ATCC is a non-profit organization with headquarters in Manassas, VA, and an R&D innovation center in Gaithersburg, MD.
Contact: Kim Testa, senior director, Corporate Communications & Public Affairs, ATCC, 703-429-0775 ext. 2753
Latest posts by BioBuzz Media (see all)
- Adaptive Phage Therapeutics Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, to Chief Medical Officer - July 30, 2021
- Delaware allocates additional $10M for Ready-to-Go Lab Space Grants - July 29, 2021
- Mason’s Michael Buschmann and team at start-up AexeRNA Therapeutics Inc. pursue patents for improved COVID-19 vaccines - July 29, 2021
- Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility - July 29, 2021
- MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market - July 29, 2021